Our Portfolio • ALLO-501: Phase 1 R/R NHL • ALLO-715: IND Accepted for MM • UCART19: Phase 1 Adult and Pediatric ALL (Servier Sponsored) Our Capital •$681 million in • Pipeline: 15 additional tumor targets cash and investments as of 3/31/19 Our Locations • Headquarters in South San Francisco • Office in New York Our People • Manufacturing facility •~160 employees planned in Newark, CA Our Foundation •3 Key Agreements created in the Foundation 6
{}